Publications scientifiques en 2024

Depuis le 05/01/2026
  1. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study).
    Lemaitre F, Lagoutte-Renosi J, Gagnieu MC, Parant F, Venisse N, Grégoire M, Bouchet S, Garraffo R, Lê MP, Muret P, Comets E, Solas C, Peytavin G; ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43.
    Br J Clin Pharmacol. 2024
  2. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    de Germay S, Pambrun E, Pariente A, Grenet G, Bezin J, Faillie JL.
    Diabetes Obes Metab. 2024
  3. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network.
    Gandolfo P, Soeiro T, Jouve É, Revol B, Daveluy A, Bertin C, Eiden C, Gibaja V, Chaouachi L, Pérault-Pochat MC, Chevallier C, Aquizérate A, Le Boisselier R, Carton L, Lapeyre-Mestre M, Frauger É, Lacroix C, Micallef J.
    Fundam Clin Pharmacol. 2024
  4. Hexahydrocannabinol poisoning reported to French poison centres.
    Labadie M, Nardon A, Castaing N, Bragança C, Daveluy A, Gaulier JM, El Balkhi S, Grenouillet M; French Poison Centre Research Group; Christine Tournoud.
    Clin Toxicol (Phila). 2024
  5. Resective epilepsy surgery and its impact on depression in adults: a systematic review, meta-analysis, and implications for future research.
    Hernandez Poblete N, Gay F, Salvo F, Micoulaud-Franchi JA, Bienvenu T, Coelho J, Aupy J.
    J Neurol Neurosurg Psychiatry. 2024
  6. Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis.
    Raschi E, Salvo F, Bate A, De Ponti F, Poluzzi E, Tuccori M, van Puijenbroek E, Joshi N, Khouri C.
    Drug Saf. 2024
  7. Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data.
    Cicala G, Barbieri MA, Russo G, Salvo F, Spina E.
    Pharmaceuticals (Basel). 2024
  8. Strategies for Identifying Biomarkers in Severe Asthma.
    Girodet PO.
    Am J Respir Crit Care Med. 2024
  9. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study).
    Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P.
    Lancet Reg Health Eur. 2024
  10. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C.
    Drug Saf. 2024
  11. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
    Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C.
    Drug Saf. 2024
  12. Can We Ask ChatGPT About Drug Safety? Appropriateness of ChatGPT Responses to Questions About Drug Use and Adverse Reactions Received by Pharmacovigilance Centers.
    Pariente A, Salvo F, Bres V, Faillie JL.
    Drug Saf. 2024
  13. Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021.
    Fernandez J, Babin C, Thomassin C, Pelon F, Kelley S, Cochat P, Galbraith M, Berdaï D, Pariente A, Salvo F, Vanier A.
    Int J Technol Assess Health Care. 2024
  14. Tyrosine Kinase Inhibitors in Cancers: treatment optimization - Part I.
    Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, Ciccolini J, Meyer N, Paci A.
    Crit Rev Oncol Hematol. 2024
  15. Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.
    Ferrer F, Tetu P, Dousset L, Lebbe C, Ciccolini J, Combarel D, Meyer N, Paci A, Bouchet S.
    Crit Rev Oncol Hematol. 2024
  16. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study.
    Guillot J, Justice AC, Gordon KS, Skanderson M, Pariente A, Bezin J, Rentsch CT.
    J Gen Intern Med. 2024
  17. Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase.
    Maillard O, Bun R, Laanani M, Verga-Gérard A, Leroy T, Gault N, Estellat C, Noize P, Kaguelidou F, Sommet A, Lapeyre-Mestre M, Fourrier-Réglat A, Weill A, Quantin C, Tubach F.
    Therapie. 2024
  18. Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic.
    Cracowski JL, Molimard M, Richard V, Roustit M, Khouri C.
    Expert Opin Drug Saf. 2024
  19. Reader Response: Cumulative Use of Proton Pump Inhibitors and Risk of Dementia: The Atherosclerosis Risk in Communities Study.
    Khouri C, Pariente A.
    Neurology. 2024
  20. Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life.
    Taillé C, Humbert M, Bourdin A, Thonnelier C, Lajoinie A, Chassetuillier J, Molimard M, Deschildre A.
    ERJ Open Res. 2024
  21. GLP-1 Receptor Agonists and Suicidality-Caution Is Needed.
    Salvo F, Faillie JL.
    JAMA Netw Open. 2024
  22. [Therapeutic management and adjustment of long-term treatment]
    Drummond D, Mazenq J, Lezmi G, Cros P, Coutier L, Desse B, Divaret-Chauveau A, Dubus JC, Girodet PO, Kiefer S, Llerena C, Pouessel G, Troussier F, Werner A, Schweitzer C, Lejeune S, Giovannini-Chami L.
    Rev Mal Respir. 2024
  23. Tiny pills, big impacts: A systematic review on the endocrine disrupting effects of paediatric pharmaceuticals.
    Tourvieilhe L, Salvo F, Bréant V, Kassai B, Portefaix A.
    Environ Toxicol Pharmacol. 2024
  24. Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
    Khouri C, Hlavaty A, Revol B, Salvo F, Raschi E.
    Ther Adv Neurol Disord. 2024
  25. A case of lenacapavir use for preventing mother-to-child HIV transmission.
    Hémar V, Bouchet S, Ribeiro E, Prier P, Elleau C, Solas C, Destere A, Hessamfar M, Tumiotto C, Bonnet F.
    J Antimicrob Chemother. 2024
  26. Suicidal behaviour and CFTR modulators: A case series and WHO database disproportionality analysis.
    Nidegger I, Macey J, Ferey M, Singier A, Tournier M, Perino J, Salvo F.
    J Cyst Fibros. 2024
  27. Correction to "Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)" [The Lancet Regional Health - Europe 41 (2024) 100915]
    Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P.
    Lancet Reg Health Eur. 2024
  28. Éthique et recherche clinique : quelles évolutions pour les CPP et les comités d’éthique de la recherche ?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2024
  29. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.
    Fusaroli M, Salvo F, Khouri C, Raschi E.
    Front Pharmacol. 2024
  30. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.
    Bezin J, Bénard-Laribière A, Hucteau E, Tournier M, Montastruc F, Pariente A, Faillie JL.
    EClinicalMedicine. 2024